Read by QxMD icon Read


Leah Drost, Vithusha Ganesh, Bo Angela Wan, Carlo DeAngelis, Mark Pasetka, May Tsao, Elizabeth Barnes, Hans Chung, Edward Chow
BACKGROUND: Pelvic radiation may cause radiation enteritis, which commonly manifests as diarrhea. Radiation to the abdomen or pelvis may also cause radiation-induced nausea and vomiting (RINV) which is often treated with anti-emetics such as serotonin (5-HT3) receptor antagonists (RA). However, a common side effect of these anti-emetic medications is constipation. Both diarrhea and constipation can have a significant impact on patient quality of life (QOL). The objective of this study was to assess the prevalence of diarrhea and constipation in patients receiving pelvic radiation and anti-emetics...
June 3, 2017: Annals of Palliative Medicine
Kristopher Dennis, Rehana Jamani, Clare McGrath, Leila Makhani, Henry Lam, Patrick Bauer, Carlo De Angelis, Natalie Coburn, C Shun Wong, Edward Chow
PURPOSE: Clinical trials in radiation therapy-induced nausea and vomiting (RINV) appear to have varied methodologies, endpoints, and outcome measures. This complicates trial comparisons, weakens practice guideline recommendations, and contributes to variability in supportive care patterns of practice. We systematically reviewed RINV trials to describe and compare their pertinent design features. MATERIALS AND METHODS: Ovid versions of the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, EMBASE, and MEDLINE to January/February 2017 were searched for adult phase III trials of RINV management strategies...
June 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Wing S Li, Joanne M van der Velden, Vithusha Ganesh, Sherlyn Vuong, Srinivas Raman, Marko Popovic, Henry Lam, Kam H Wong, Roger K Ngan, J P Maarten Burbach, Carlo DeAngelis, Rachel McDonald Xxxx, Edward Chow
BACKGROUND: The aim of this article was to systematically review the efficacy and safety of various antiemetics in prophylaxis of radiation-induced nausea and vomiting (RINV). METHODS: A literature search of Ovid MEDLINE, EMBASE and Cochrane CENTRAL was performed to identify randomized controlled trials (RCTs) that evaluated the efficacy of prophylaxis for RINV in patients receiving radiotherapy to abdomen/pelvis, including total body irradiation (TBI). Primary endpoints were complete control of nausea and complete control of vomiting during acute and delayed phases...
April 2017: Annals of Palliative Medicine
Steven Ades, M Halyard, K Wilson, T Ashikaga, R Heimann, S Kumar, W Blackstock
PURPOSE: Despite a lower risk of nausea and vomiting in patients receiving radiotherapy to the upper abdomen (UA-RINV) with prophylactic 5-HT3 antagonist therapy, patients can still experience UA-RINV. The aim of this multicenter phase II study was to assess effectiveness, safety, and tolerability of protracted dual NK1-receptor and 5-HT3 antagonist prophylaxis against UA-RINV. METHODS: Patients receiving fractionated radiotherapy with radiosensitizing chemotherapy received oral ondansetron 8 mg po q12 h and aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedules throughout radiotherapy...
May 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Deepti Ahuja, Sachidanand J Bharati, Nishkarsh Gupta, Ritesh Kumar, Sushma Bhatnagar
Radiation-induced nausea and vomiting (RINV) is one of the most distressing symptoms that adversely affects quality of life (QOL) as well as the ongoing management plan of cancer patients. Although there are protocols for management of chemotherapy induced nausea and vomiting (CINV) but such guidelines are still lacking for RINV. Various agents like 5-hydroxy tryptophan 3 (5-HT3) antagonist, dexamethasone, metoclopramide and haloperidol are used in clinical practice for RINV but the results are not very encouraging...
October 2016: Annals of Palliative Medicine
Christina H Ruhlmann, Franziska Jahn, Karin Jordan, Kristopher Dennis, Ernesto Maranzano, Alexander Molassiotis, Fausto Roila, Petra Feyer
PURPOSE: Radiotherapy-induced nausea and vomiting (RINV) are distressing symptoms. Evidence-based guidelines should facilitate the prescription of the best possible antiemetic prophylaxis. As part of the MASCC/ESMO Antiemetic Guidelines Update 2016, a thorough review of the literature concerning RINV since the 2009 update was required. METHODS: A systematic review of the literature including data published from June 2009 to May 2015 was performed. Committee VII (RINV) under the MASCC/ESMO Antiemetic Guidelines Update Committee assessed the literature...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Cheryl Vidall, Sangeeta Sharma, Bharat Amlani
This UK cohort analysis of a European survey evaluated the differences between health professionals and cancer patients regarding the perceived incidence, impact and drug management of chemotherapy/radiotherapy-induced nausea/vomiting (CINV/RINV). The UK healthcare system is unique in that it has dedicated oncology clinical nurse specialists. The analysis found that more patients experienced nausea following their most recent treatment cycle than vomiting. Health professionals overestimated the incidence of CINV/RINV but underestimated its impact on patients' daily lives, particularly in cases of mild and moderate nausea/vomiting...
September 8, 2016: British Journal of Nursing: BJN
Mohsen Habibi, Amir Namimoghadam, Roghaye Korouni, Paria Fashiri, Sajad Borzoueisileh, Farideh Elahimanesh, Fatemeh Amiri, Ghobad Moradi
Despite the improvements in cancer screening and treatment, it still remains as one of the leading causes of mortality worldwide. Nausea and vomiting as the side effects of different cancer treatment modalities, such as radiotherapy, are multifactorial and could affect the treatment continuation and patient quality of life. Therefore, the aim of this study was to assess the possible linkage between ABO blood groups and radiation-induced nausea and vomiting (RINV), also its incidence and affecting factors.One hundred twenty-eight patients referring to Tohid hospital of Sanandaj, Iran, were selected and the patients and treatment-related factors were determined in a cross-sectional study...
August 2016: Medicine (Baltimore)
Christina H Ruhlmann, Jørn Herrstedt
INTRODUCTION: Antiemetic prophylaxis for the prevention of chemotherapy-induced nausea and vomiting, and the development of new antiemetic drugs are expanding areas of research. However, studies of antiemetic prophylaxis in chemoradiotherapy have not been prioritised, and little is known about the proper timing, duration, and combination of antiemetic drugs for the prevention of chemoradiotherapy-induced nausea and vomiting (C-RINV). AREAS COVERED: The article summarises the available antiemetic studies, the evidence for antiemetic prophylaxis of C-RINV, and the future perspectives for antiemetic research in chemoradiotherapy...
August 2016: Expert Opinion on Pharmacotherapy
Sophie Morin, Irina Leurs, Marie-Noëlle Bousquet, Florian Scotté
INTRODUCTION: Despite progress in the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV), their management remains insufficient. METHODS: In order to evaluate the incidence and impact of CINV/RINV on the quality of life perceived by patients and estimated by clinicians, a declarative, cross-sectional survey was conducted in France through an online questionnaire. RESULTS: This survey included 187 participants: 75 oncologists, 35 oncology nurses and 77 patients...
May 2016: Bulletin du Cancer
Nicholas Chiu, Leonard Chiu, Marko Popovic, Carlo DeAngelis, Mark Pasetka, Stephen Lutz, Na Zhang, Gustavo Nader Marta, Lucas Castro Mendez, Breanne Lechner, Natalie Pulenzas, Milica Milakovic, Ronald Chow, Edward Chow
Palliative radiotherapy (RT) is an effective treatment for symptomatic bone metastases. However, pain flare, nausea and vomiting are common adverse effects associated with this treatment. The management of pain flare and radiation-induced nausea and vomiting (RINV) are important endpoints in palliative care. Our report documents the incidence, clinical importance, and advances in the management of these two adverse-effects. We recommend that antiemetic prophylaxis be given based on emetic risk category as outlined in the American Society of Clinical Oncology (ASCO) guidelines...
January 2016: Annals of Palliative Medicine
Petra Feyer, Franziska Jahn, Karin Jordan
The incidence of nausea and vomiting after radiotherapy is often underestimated by physicians, though some 50-80% of patients may experience these symptoms. The occurrence of radiotherapy-induced nausea and vomiting (RINV) will depend on radiotherapy-related factors, such as the site of irradiation, the dosing, fractionation, irradiated volume, and radiotherapy techniques. Patients should receive antiemetic prophylaxis as suggested by the international antiemetic guidelines based upon a risk assessment, taking especially into account the affected anatomic region and the planned radiotherapy regimen...
2015: BioMed Research International
Michael Poon, Jonathan Hwang, Kristopher Dennis, Carlo DeAngelis, Liying Zhang, Hans Chung, Jordan Stinson, Shun Wong, Natalie Pulenzas, Edward Chow
PURPOSE: Nausea and vomiting are common side effects from radiotherapy that can interfere with gastrointestinal (GI) cancer patients' quality of life (QOL). This study described the subjective experience of patients with radiation-induced nausea and vomiting (RINV) and its relation to QOL. METHODS: Forty-eight patients treated with abdominal radiotherapy alone or with concomitant chemoradiotherapy were followed in a prospective study. All episodes of nausea, vomiting, and antiemetic use were recorded daily for the treatment period and the week following completion of therapy...
April 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Hamid Emami, Simin Hematti, Seyed Masoud Saeidian, Awat Feizi, Shahin Taheri, Pourya Adeli, Golshan Mahmoudi
BACKGROUND: Depending on the site of irradiation, about 40-80% of patients undergoing radiotherapy (RT) will experience nausea and/or vomiting. The current study aimed to investigate the efficacy of ondansetronas as a single agent and with a combination to aprepitant on preventing RT-induced nausea and vomiting (RINV). MATERIALS AND METHODS: In a clinical randomized controlled trial (from September 2010 to September 2011), conducted in Radiation Oncology Department of Seyed-al-Shohada Hospital, Isfahan University of Medical Sciences, 40 abdominopelvic malignancies cancer patients were allocated into two aliquots using block randomization of size...
April 2015: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
E Wong, N Pulenzas, G Bedard, C DeAngelis, L Zhang, M Tsao, C Danjoux, N Thavarajah, B Lechner, R McDonald, P M Cheon, E Chow
INTRODUCTION: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (rdf) in the prophylaxis of radiation-induced nausea and vomiting (rinv). Rapidly dissolving film formulations facilitate drug delivery in circumstances in which swallowing the medication might be difficult for the patient. METHODS: Patients undergoing palliative radiotherapy at risk for rinv were prescribed ondansetron rdf 8 mg twice daily while on treatment and were asked to complete a nausea and vomiting-specific daily diary, the Functional Living Index-Emesis (flie), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C15 Palliative (qlq-C15-pal)...
June 2015: Current Oncology
Cheryl Vidall, Paz Fernández-Ortega, Diego Cortinovis, Patrick Jahn, Bharat Amlani, Florian Scotté
PURPOSE: Chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV) can affect half of oncology patients, significantly impacting daily life. Nausea without vomiting has only recently been thought of as a condition in its own right. As such, the incidence of nausea is often underestimated. This survey investigated the incidence and impact of CINV/RINV in patients compared with estimations of physicians/oncology nurses to determine if there is a perceptual gap between healthcare professionals and patients...
November 2015: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Kristopher Dennis, Michael Poon, Edward Chow
PURPOSE OF REVIEW: Radiation therapy-induced nausea and vomiting (RINV) are common and troublesome symptoms among patients receiving radiation therapy for gastrointestinal cancers. Their impact on function, quality of life and, ultimately, cancer control warrant a review of their incidence, underlying mechanisms, treatments and research themes. RECENT FINDINGS: Research in RINV is underrepresented relative to that in chemotherapy-induced nausea and vomiting. The incidence of RINV among patients receiving modern day radiation therapy is questioned and supportive care practice patterns vary among radiation oncologists...
June 2015: Current Opinion in Supportive and Palliative Care
Leigha Rowbottom, Mark Pasetka, Rachel McDonald, Lise Hunyh, Srinivas Raman, Carlo DeAngelis, Edward Chow
BACKGROUND: Radiotherapy-induced nausea and vomiting (RINV) is a toxicity that can occur in 40-80% of individuals who receive radiation treatment. Current guidelines recommend 5-hydroxytryptamine3 receptor antagonists (5-HT3 RAs) for prophylaxis of RINV for moderate and highly emetogenic radiotherapy; however, certain patients may suffer from RINV despite prophylaxis. CASE PRESENTATION: This report details the case of a 47-year-old female with extensive bony involvement to the spine from breast cancer presenting with lower back pain...
January 2015: Annals of Palliative Medicine
Michael Poon, Kristopher Dennis, Carlo DeAngelis, Hans Chung, Jordan Stinson, Liying Zhang, Gillian Bedard, Erin Wong, Marko Popovic, Nicholas Lao, Natalie Pulenzas, Shun Wong, Paul Cheon, Edward Chow
OBJECTIVE: The Functional Living Index-Emesis (FLIE) instrument is a validated nausea and vomiting specific quality of life (QOL) tool originally created as a 3-day test of the impact of chemotherapy-induced nausea and vomiting on cancer patients' daily life. The primary objective of the present study was to retrospectively explore the use of the FLIE from data obtained in a previously published study of patients with gastrointestinal radiation-induced nausea and vomiting (RINV) and compare the extracted symptom clusters on a weekly basis for the entirety of gastrointestinal cancer patients' radiotherapy treatments...
September 2015: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
K Dennis, C De Angelis, F Jon, N Lauzon, M Pasetka, L Holden, E Barnes, C Danjoux, A Sahgal, M Tsao, E Chow
PURPOSE: We evaluated the novel combination of aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting (rinv) among patients receiving moderately-emetogenic radiotherapy for thoracolumbar bone metastases. METHODS: In this single-centre two-arm nonrandomized prospective pilot study, patients undergoing single-fraction radiotherapy (8 Gy) received aprepitant 125 mg and granisetron 2 mg on the day of radiotherapy and aprepitant 80 mg on each of the first 2 days after the day of radiotherapy...
December 2014: Current Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"